Key insights
- Sotera Health (SHC) announced Alton Shader as the new CEO, effective May 2026, succeeding Michael Petras, Jr., who becomes executive chairman. Shader's experience at Viant Medical and Hill-Rom suggests a focus on growth and operational efficiency. InvestingPro analysis indicates SHC is undervalued with expected net income growth and a low PEG ratio, potentially signaling a positive outlook for the stock.
CLEVELAND - Sotera Health Company (NASDAQ:SHC) announced Monday that Alton Shader will become chief executive officer effective May 26, 2026, according to a press release statement.
Shader currently serves as CEO of Viant Medical, a medical device design and manufacturing services provider, a position he has held since 2019. He will succeed Michael B. Petras, Jr., who has led the company since 2016 and will transition to executive chairman of the board.
Petras will remain a full-time employee and continue involvement in investor relations, commercial operations and litigation strategy. Under his tenure, Sotera Health’s revenue grew from $630 million in 2016 to $1.164 billion in 2025. The company completed its initial public offering on the Nasdaq Stock Market in 2020. The company now commands a market capitalization of $4.39 billion and maintains a "GOOD" financial health rating, with revenue growing 5.74% over the last twelve months.
Shader brings over 20 years of medical industry experience. At Viant Medical, he expanded the company’s global manufacturing footprint and pursued acquisitions to strengthen capabilities. Before Viant, he served as president of Hill-Rom’s global Front Line Care business and held senior positions at Baxter International Inc. in Europe and the United States.
Shader holds a bachelor’s degree in economics and psychology from Claremont McKenna College and an MBA from Stanford University.Shader inherits a company that InvestingPro analysis suggests is currently undervalued, with net income expected to grow this year. The stock trades at a PEG ratio of 0.78, indicating attractive valuation relative to its growth prospects. For investors seeking deeper insights, InvestingPro offers 6 additional exclusive tips, along with comprehensive Pro Research Reports covering SHC and 1,400+ other US equities.
"The transition to Alton has been carefully planned to ensure Sotera Health’s continued success," Petras said in the statement. "Alton’s strong commercial experience and track-record of driving growth in the healthcare industry makes him a great fit for Sotera Health."
Vincent Petrella will remain lead independent director of the board.
Sotera Health provides sterilization solutions, lab testing and advisory services for the healthcare industry through its Sterigenic, Nordion and Nelson Labs businesses.
In other recent news, Sotera Health reported its fourth-quarter earnings for 2025, exceeding analysts’ expectations with an adjusted EPS of $0.26 against the forecasted $0.24. The company’s revenue for the quarter reached $303.44 million, slightly surpassing the anticipated $299.51 million. Additionally, RBC Capital reiterated its Outperform rating for Sotera Health, maintaining a $24.00 price target following a favorable legal development in Georgia ethylene oxide litigation. This positive summary judgment is seen as reducing the legal settlement risk for the company.
In other developments, Sotera Health announced the appointment of Kenneth D. Krause to its board following the resignation of Constantine S. Mihas. Krause will serve on both the Audit and Litigation Committees. Moreover, stockholders of Sotera Health completed a secondary offering by selling 25 million shares at $15.27 each through Wells Fargo Securities. The company itself did not receive any proceeds from this transaction, as the shares were sold by certain stockholders, including private equity firms Warburg Pincus and GTCR.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.